I serve as the Assistant Director of Federal Relations for Vanderbilt University Medical Center. Views expressed are my own
Washington, DC
Joined December 2017
- Tweets269
- Following168
- Followers146
- Likes631
Nicholas Warren PhD retweeted
Honored that my first meeting in D.C. was with the Children’s Hospital Alliance of Tennessee. Their commitment to caring for our state’s children is remarkable, and I look forward to supporting their mission in Congress.
Last week I had the honor of leading the Tennessee group for the Rally for Medical Research. We had a fantastic group of researchers and patient advocates. Medical research saves lives! #FundNIH #RallyMedRes
news.vumc.org/2025/09/25/van…
Nicholas Warren PhD retweeted
A recent @CCR_AACR perspective discussed how to improve collection and analysis of #OverallSurvival data in oncology clinical trials. @WarrenNJH breaks down the key lessons on the #AACRBlog: bit.ly/3Ws9lTy
#AACRSciencePolicy
Nicholas Warren PhD retweeted
A recent @CCR_AACR perspective discussed how to improve collection and analysis of #OverallSurvival data in oncology clinical trials. A new Cancer Research Catalyst blog by @WarrenNJH breaks down the key lessons: bit.ly/4daGfP7
#AACRSciencePolicy
Proud to have helped support this new @CCR_AACR article on #OverallSurvival! A wonderful and collaborative experience with my colleagues to try to improve the quality and timeliness of trial data!
A new @CCR_AACR article by @FDAOncology, AACR, and @AmstatNews experts details how to improve the collection and analysis of #OverallSurvival data to better understand the risks and benefits of new therapies. Read the paper: bit.ly/3zOZxLQ
#AACRSciencePolicy
This is an excellent opportunity to learn about the drug development and regulatory processes from FDA experts!
The FDA-AACR Oncology Educational Fellowship provides early-career scientists and clinicians with an opportunity to learn more about drug development and the regulatory review process from @FDAOncology and AACR experts. Apply by Aug 1:
bit.ly/4aVW1fg
#AACRSciencePolicy
Nicholas Warren PhD retweeted
⬇️ Starting now!
@US_FDA Center for Tobacco Products’ Prioroties to Reduce Tobacco Use and Support the #Cancer Moonshot
Room 5, second floor.
#AACR24 @AACR @bentollphd – at San Diego, CA
Please join us this morning @AACR with @FDATobacco Director Brian King I’ll be on the panel @christine_lovly @muschollings #AACR24
Nicholas Warren PhD retweeted
Ruixiao Lu of the American Statistical Association, @AmStatNews, moderated a panel discussion on @FDAOncology's Project Endpoint and overall survival at #AACR24 today. #AACRSciencePolicy
Nicholas Warren PhD retweeted
.@DrRoyHerbstYale will moderate an #AACRSciencePolicy session to showcase the reignited #CancerMoonshot. @NCIDirector Kimryn Rathmell and other panelists will discuss how we can achieve meaningful progress to “end cancer as we know it.” bit.ly/3xoa6Eg #AACRSciencePolicy
This is a really exciting #AACR24 session on policies to address the number one cause of cancer, #Tobacco, on Monday at 10:15am PT. Please join us! #AACRSciencePolicy
Brian King, director of the FDA Center for Tobacco Products, will discuss the center's new strategic plan and other policy initiatives to address #tobacco-related illness in a special #AACRSciencePolicy session at #AACR24. Learn more: bit.ly/3U29EEv @FDATobacco
Please join us for this great #AACR24 session on overall survival this Saturday! #AACRSciencePolicy
FDA's Project Endpoint and Overall Survival in Oncology Clinical Trials: Ruixiao Lu will moderate an @FDA_Oncology session on this topic during #AACR24. Learn more: bit.ly/4aAfy5m
#AACRSciencePolicy
Nicholas Warren PhD retweeted
Please join these experts & me at #AACR24 for an engaging discussion on how to define benefit/risk with targeted oncology therapies for patients with cancer. See you in San Diego! abstractsonline.com/pp8/#!/2…
@OncoAlert #CRCSM @AACR
Nicholas Warren PhD retweeted
A proposed @FDA rule would classify laboratory-developed tests as medical devices subject to regulatory oversight. @DrTonyLetai will moderate an #AACR24 discussion of the benefits and challenges of this new regulatory framework. bit.ly/4cDDI0I
#AACRSciencePolicy
Nicholas Warren PhD retweeted
#MCED assays are a promising tool for #earlydetection of cancer, but questions remain about risk assessment in multi-cancer settings and use in clinical practice. Lauren Leiman will moderate an #AACR24 discussion of the future of MCED. bit.ly/49f7i9S
#AACRSciencePoilcy
Nicholas Warren PhD retweeted
Today is the AACR Early-Career National Day of Action, and we're calling on early-career scientists, trainees, students, and all who support them to contact members of Congress and ask them to prioritize @NIH funding. Take action: AACR.org/AACRECHD24 #AACRontheHill #FundNIH
Thank you to everyone who made this event a success! #AACRSciencePolicy
Thanks to everyone who participated in today's @US_FDA_Oncology-AACR Workshop on Optimizing Dosages for Oncology Drug Products. Session recordings and slides will be posted to the AACR website by Thursday, February 22. Learn more: bit.ly/498SYAp #AACRSciencePolicy
Nicholas Warren PhD retweeted
Thanks to everyone who participated in today's @US_FDA_Oncology-AACR Workshop on Optimizing Dosages for Oncology Drug Products. Session recordings and slides will be posted to the AACR website by Thursday, February 22. Learn more: bit.ly/498SYAp #AACRSciencePolicy
Nicholas Warren PhD retweeted
AACR President-Elect Patricia M. LoRusso moderated a panel discussion on lessons learned and next steps to close out the @US_FDA-AACR dosage optimization workshop. We thank the moderators, speakers, and panelists, for their contributions to this vital event. #AACRSciencePolicy
Nicholas Warren PhD retweeted
AACR President-Elect Patricia M. LoRusso and @FDAOncology’s Marc Theoret opened today's FDA-AACR Workshop on Optimizing Dosages for Oncology Drug Products. Participants will share examples of and rationales behind effective dosage optimization strategies. #AACRSciencePolicy
Nicholas Warren PhD retweeted
AACR President-Elect and #AACRFellows Patricia M. LoRusso, DO, PhD (hc), was quoted in this AP story about reducing doses of chemotherapy drugs to minimize side effects. Dr. LoRusso will chair an AACR-@US_FDA workshop on this topic Feb 15-16. Learn more:
aacr.org/professionals/polic…
As cancer treatment advances, patients and doctors push back against drugs' harsh side effects apnews.com/article/cancer-tr…
